crta
Hrvatska znanstvena Sekcija img
bibliografija
3 gif
 Naslovna
 O projektu
 FAQ
 Kontakt
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Upute
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 782038

Zbornik radova

Autori: Žutelija, Marta; Majurec, Iva; Klanac, Ana; Mikolašević, Ivana; Zibar, Lada; Begić, Ivana; Jakopčić, Ivan; Šimundić, Tihana; Minažek, Marija; Imbrishich, Svjetlana; Rački, Sanjin; Orlić, Lidija
Naslov: RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS LOWERS HEMATOCRIT AND HEMOGLOBIN LEVELS ONLY IN THOSE RENAL TRANSPLANT RECIPIENTS WITH INITIALLY HIGHER HEMOGLOBIN AND HEMATOCRIT LEVELS
( RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS LOWERS HEMATOCRIT AND HEMOGLOBIN LEVELS ONLY IN THOSE RENAL TRANSPLANT RECIPIENTS WITH INITIALLY HIGHER HEMOGLOBIN AND HEMATOCRIT LEVELS )
Izvornik: BANTAO Journal
ISSN: 1312-2517
Skup: 12th Congress of the Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs 6th Croatian Symposium on Renal Replacment Therapy
Mjesto i datum: Opatija, Hrvatska, 15-18. listopada, 2015.
Ključne riječi: RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS; RENAL TRANSPLANT RECIPIENTS
( RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS; RENAL TRANSPLANT RECIPIENTS )
Sažetak:
AIM: We analyzed the effects of the angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor type 1 blockers (ARBs) on the evolution of hematocrit (Htc) and hemoglobin (Hgb) levels in stable renal transplant patients (RTRs) with respect to higher and lower initial hemoglobin and hematocrit values. We also wished to determine if these agents have an effect on the evolution of kidney graft function with respect to higher and lower initial hemoglobin and hematocrit values. METHODS: The study group comprised of 270 RTRs (158 male) with stable graft function. Beside other prescribed antihypertensive drugs, 85 of them took ACE-I and 84 ARBs as a part of their antihypertensive therapy. On the other hand, 101 RTRs didn’t have prescribed ACE-I/ARBs. RESULTS: After analyzing the hemoglobin, hematocrit, creatinine and potassium serum levels after initiation of therapy with ACE-I and ARB or no therapy with ACE-I/ARBs trough a 12-month period, we haven’t found any significant difference in hemoglobin, hematocrit, creatinine and potassium levels in those three groups of patients. On the other hand, in patients with initially higher Hgb (Hgb ≥150 g/L) and initially higher Htc (Htc ≥ 45%) levels there was a statistically significant decrease in hemoglobin (p=0.006) and hematocrit (p<0.0001) levels after 12-months of follow up. Additionally, in the group of patients with initially lower Hgb (Hgb<150 g/L) and initially lower Htc (Htc<45) levels there was a significant increase in hemoglobin (p=0.0001) and hematocrit (p=0.004) levels through observed period. The use of ACE-I/ARBs was associated with a trend of slowing renal insufficiency in RTRs (p=0.03). CONCLUSION: ACE-I and ARBs lower hematocrit and hemoglobin levels only in those RTRs with initially higher hemoglobin and hematocrit levels. In patients with initially lower hemoglobin and hematocrit levels the use of these drugs has a beneficial impact on erythropoiesis and kidney graft function.
Rad je indeksiran u
bazama podataka:
Scopus
Vrsta sudjelovanja: Predavanje
Vrsta prezentacije u zborniku: Sažetak
Vrsta recenzije: Međunarodna recenzija
Izvorni jezik: eng
Kategorija: Znanstveni
Znanstvena područja:
Kliničke medicinske znanosti
Upisao u CROSBI: Sanjin Rački (sanjin.racki@uniri.hr), 18. Lis. 2015. u 16:50 sati



Verzija za printanje   za tiskati


upomoc
foot_4